EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

How ‘miracle’ weight‐loss semaglutide promises to change medicine but can we afford the expense?

Ralf Weiskirchen iD, Amedeo Lonardo

British Journal of Pharmacology · 2025-04 · 182 (8) · 1651-1670

DOI: 10.1111/bph.70003 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift British Journal of Pharmacology, online erschienen am 13.02.2025. Verfasst von Ralf Weiskirchen und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), RWTH University Hospital Aachen, Aachen, Germa…. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Weight Loss, Obesity, Anti-Obesity Agents. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 121 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Obesity is a complex and growing global concern, affecting one in eight individuals and compromising health, quality of life and life expectancy. It carries significant metabolic, cardiovascular, oncological, hepatorenal, skeletal and psychiatric risks, imposing substantial costs on health‐care systems. Traditional treatments have often been ineffective or have led to relapse after lifestyle changes. Whereas bariatric surgery is effective, it also involves risks such as mortality and hospitalisation. Semaglutide, licensed in 2018, is a synthetic analogue of glucagon‐like peptide 1 which regulates glucose metabolism and gastrointestinal (GI) motility. Studies show that semaglutide, administered either weekly and subcutaneously, or daily orally, induces an average weight loss of −11.62 kg compared to placebo and reduces waist circumference by up to −9.4 cm. It also improves blood pressure, fasting glucose levels, C‐reactive protein levels and lipid profiles. The most common adverse events are mild‐to‐moderate GI complaints occurring more frequently with daily administration than weekly doses; hypoglycaemia is more common without lifestyle intervention. Weight regain often follows semaglutide withdrawal. Furthermore, semaglutide offers cardiovascular benefits for patients with established atherosclerotic cardiovascular disease (CVD), lowers the risk of kidney outcomes and cardiovascular‐related death, resolves nonalcoholic steatohepatitis in many cases, and positively impacts mental health and quality of life. In conclusion, semaglutide therapy could significantly benefit many adults regarding CVD and mortality if made widely accessible. Ethical and financial considerations must be addressed for personalised obesity treatment approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like PeptidesWeight LossObesityAnti-Obesity AgentsHumansAnimalsGlucagon-Like Peptide 1Semaglutide

Stichwörter der Autor:innen

GLP‐1 receptor agonistcancer, chronic kidney disease, drug adverse effectshealth‐care costsmajor adverse cardiovascular eventsmental healthmetabolic dysfunction‐associated steatotic liver diseasemetabolic functionobesitypersonalised medicinepharmacoeconomicsquality of lifetype 2 diabetesweight loss

Substanzen

Glucagon-Like PeptidesAnti-Obesity AgentsGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), RWTH University Hospital Aachen, Aachen, Germany.
  • Department of Internal Medicine, Azienda Ospedaliero-Universitaria of Modena (2023), Modena, Italy.

ORCID-Profile: Ralf Weiskirchen

Zitieren

APA

Weiskirchen, R., & Lonardo, A. (2025). How ‘miracle’ weight‐loss semaglutide promises to change medicine but can we afford the expense?. British Journal of Pharmacology, 182(8), 1651-1670. https://doi.org/10.1111/bph.70003

Vancouver

Weiskirchen R, Lonardo A. How ‘miracle’ weight‐loss semaglutide promises to change medicine but can we afford the expense?. British Journal of Pharmacology. 2025;182(8):1651-1670. doi:10.1111/bph.70003

BibTeX
@article{Weiskirchen2025,
  author = {Weiskirchen, Ralf and Lonardo, Amedeo},
  title = {How ‘miracle’ weight‐loss semaglutide promises to change medicine but can we afford the expense?},
  journal = {British Journal of Pharmacology},
  year = {2025},
  volume = {182},
  number = {8},
  pages = {1651--1670},
  doi = {10.1111/bph.70003}
}
Kostenlos starten →